Omeros Corporation (OMER)
Healthcare
Biotechnology
11.80 $
-0.8%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Omeros Corporation (OMER)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 96.4% of the shares are freely tradable; institutional investors hold 44.5%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
44.5%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
3.6%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
96.4%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
25.9%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
72Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 7.34 | 5,309,626 | +4.9 | 03/31/2026 |
| Vanguard Group Inc | 5.55 | 4,013,315 | +19.9 | 12/31/2025 |
| Ingalls & Snyder LLC | 4.92 | 3,559,423 | +3.2 | 03/31/2026 |
| Vanguard Capital Management, LLC | 4.12 | 2,983,259 | +0.0 | 03/31/2026 |
| UBS Group AG | 3.23 | 2,340,731 | +5.3 | 03/31/2026 |
| State Street Corp | 2.65 | 1,919,575 | +22.0 | 03/31/2026 |
| Stifel Financial Corp | 2.53 | 1,831,585 | +1.2 | 03/31/2026 |
| Geode Capital Management, LLC | 2.42 | 1,752,323 | +7.4 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 2.93 | 2,120,336 | +0.0 | 04/30/2026 |
| iShares Russell 2000 ETF | 2.27 | 1,640,404 | +0.9 | 05/29/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.